DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION
  • Stocks
  • /
  • Pharmaceuticals & Biotech
Updated 1h ago
CYPA logo

Cyphaira Corp.OTCPK:CYPA Stock Report

Market Cap US$39.2m
Updated 1h ago
Share Price
n/a
1Yn/a
7D0%
1D-17.0%
Portfolio Value
​
View

Cyphaira Corp.

OTCPK:CYPA Stock Report

Market Cap: US$39.2m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Cyphaira (CYPA) Stock Overview

Engages in the sowing of the seeds for cultivation and selling of cannabis. More details

CYPA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Shares are highly illiquid

Latest financial reports are more than a year old

Shareholders have been diluted in the past year

Does not have a meaningful market cap ($39M)


CYPA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW438,352 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
438,352 investors already sharing narratives
US$
Current Price
US$1.223.2k% overvalued intrinsic discount
%/yr
Decrease
Increase
PastFuture-408k583k2016201920222025202620282031Revenue US$583.3kEarnings US$86.6k
Advanced
View all narratives

Cyphaira Corp. Competitors

Filana Therapeutics

Symbol: NasdaqCM:FLNA
Market cap: US$39.1m

Incannex Healthcare

Symbol: NasdaqCM:IXHL
Market cap: US$38.6m

Nasus Pharma

Symbol: NYSEAM:NSRX
Market cap: US$41.6m

Veru

Symbol: NasdaqCM:VERU
Market cap: US$42.3m

Price History & Performance

Summary of share price highs, lows and changes for Cyphaira
Historical stock prices
Current Share PriceUS$1.22
52 Week HighUS$3.00
52 Week LowUS$1.05
Beta0
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO388.00%

Recent News & Updates

Recent updates

Shareholder Returns

CYPAUS PharmaceuticalsUS Market
7D0%-4.0%-2.2%
1Yn/a43.7%13.1%

Return vs Industry: Insufficient data to determine how CYPA performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CYPA performed against the US Market.

Price Volatility

Is CYPA's price volatile compared to industry and market?
CYPA volatility
CYPA Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement8.8%
Market Average Movement6.9%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.9%

Stable Share Price: CYPA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine CYPA's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2021n/aJoseph Babiakwww.growthstalk.com

Cyphaira Corp. engages in the sowing of the seeds for cultivation and selling of cannabis. It also engages in the production and processing of exotic cannabis flowers, extracts and bubble hash, and live rosin from the trim of the flower. The company was formerly known as Growth Stalk Holdings Corp. and changed its name to Cyphaira Corp. in September 2026.

Cyphaira Corp. Fundamentals Summary

How do Cyphaira's earnings and revenue compare to its market cap?
CYPA fundamental statistics
Market capUS$39.17m
Earnings (TTM)-US$311.16k
Revenue (TTM)US$583.34k
0.0x
P/S Ratio
0.0x
P/E Ratio

Is CYPA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CYPA income statement (TTM)
RevenueUS$583.34k
Cost of RevenueUS$404.21k
Gross ProfitUS$179.13k
Other ExpensesUS$490.30k
Earnings-US$311.16k

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did CYPA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 18:04
End of Day Share Price 2026/06/30 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cyphaira Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide